VIR-5525 is an investigational EGFR-targeting PRO-XTEN dual-masked T-cell engager in first-in-human Phase 1 evaluation for EGFR-expressing solid tumors. The trial is testing monotherapy and combination with pembrolizumab across tumor types such as NSCLC, colorectal cancer, head and neck squamous cell carcinoma, and cutaneous squamous cell carcinoma. It is not approved for marketing.
Vir Biotechnology has dosed the first patient in a Phase I VIR-5500 expansion cohort for metastatic prostate cancer. The trial is evaluating VIR-5500 as monotherapy and in combination settings across mCRPC and mHSPC.
Vir Biotechnology reported Q4 EPS of ($0.31), beating estimates by $0.23, with revenue of $64.07 million. The company announced a global strategic collaboration with Astellas for VIR-5500 and reported $781.6 million in cash and investments.
Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06960395 |
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE1 |
